Invest in Radiolife

Disruptive cutting-edge diagnostic platform. (RF + AI = Pathogens fingerprints)

EARLY BIRD TERMS: $9,627 LEFT

$40,373

of a $50,000 goal

INVEST

min $100

INVESTMENT TERMS

$14M $12M valuation cap Future Equity

Early Bird Bonus: The first $50K of investments will be in a SAFE with a $12M valuation cap and 15% discount

LEAD INVESTOR

I invested in Radiolife because of their ambitious mission to improve quality of life through technology. POSITIVITY, IMPACT & LONGEVITY! I’ve known Sergio & Willians for over a year now and I can vouch for his ability to get things done. Having had a successful exit in the past, in a very regulated industry like Telecommunications in Brazil, he has what it takes to bring this amazing breakthrough technology to the market, disrupting how diagnostics are done today.

radiolife.co

Wilmington DE

Technology Healthcare Hardware Science & R&D

Highlights

Precise results in under 20 seconds

📜 Patent granted - Proprietary technology based on RF signature & AI modeling

User-friendly and Portable

Can be remotely upgraded with new diagnostic models or for new/different diseases

Approved by ISP - Chilean Health Institute for detection of Covid-19 in nasopharyngeal samples 💪

Doesn't require complex laboratory infrastructure, additional accessories, or supplies

Our Team

The world population needs a low-cost method that allows diseases to be diagnosed in a faster and more accurate fashion. Overcoming the current vulnerability to disease outbreaks and the diagnosis of epidemic/pandemic pathogens is our main goal at RadioLife.

Why Radiolife?

DISCLAIMER

Information provided herein is for the purpose of fundraising
Cube Scan is an Investigational Medical device in all countries other than Chile
Claims have not been evaluated by health authorities other than ISP – Chilean Public Health Institute

The Problem:

The world needs better diagnostics solutions

There’s no readily available test for new diseases and current solutions are heavily reliant on reagents making them slow, expensive, and susceptible to supply chain bottlenecks.

Also, available testing solutions rely on complex laboratory infrastructure or methods that are too expensive to be adopted in mass testing strategies, ultimately leading to a bad patient experience.

To improve the way we do diagnostics, several health-oriented actions are required. A pivotal one is having the ability to detect the presence of a given pathogen with both accuracy and speed, in a cost-effective manner. In order to achieve this capability we need to grant universal access to accurate, affordable, safe, reliable, and most importantly, scalable diagnostic technology which could be used as a point of care device as well as in mass testing scenarios.

Radiolife is developing a fast, accurate, and portable diagnostic device called Cube Scan™ for in-vitro diagnosis of infectious diseases/pathogens.

How it works:

Our recently granted patent is based on Radiofrequency signatures combined with Artificial Intelligence modeling and it is based on the principle of magnetic reluctance, where each sample solution will resonate in a unique way creating a fingerprint that can be captured by a random forest machine learning process.

As an investigational medical device, it has the potential to detect the presence of different types of viruses, bacteria, and cancer cells, since all these biostructures resonate with the wavelengths of harmonic frequencies within the spectrum of our technology. This method was validated for Covid-19 detection with a 99.97% accuracy.

Our team is excited to expand it to other diseases and bring it to the market.

*Validated in a Brazilian Governmental Public Health lab in the state of Espírito Santo and approved in Chile by ISP – Chilean Public Health Institute for nasopharyngeal swab samples. The detection of SARS-Cov-2 in saliva samples was not approved by any Health Authority yet.

Through its capability of being remotely upgradable, CubeScan was designed to last. As new machine-learning diagnostic models are developed by Radiolife's R&D team, a simple and fast download will update your CubeScan to be ready to better diagnose current diseases or the presence of new pathogens, and help humankind to prevent and deter new pandemics.

Forward-looking projections cannot be guaranteed.

Clinical Studies – Lacen Validation

A clinical study was conducted at a Brazilian Governmental Public Health lab in the state of Espírito Santo, which allowed us to improve the analytical performance and achieve an accuracy of 99.77% for SARS-CoV-2 detection. Clinical performance was validated in a double-blind test with a large number of samples (n= 1,357), which were tested in parallel with SARS-CoV-2 specific RT-PCR kits

ISP Approval of CubeScan

Chilean Health Institute approval for detection of Covid-19 in nasopharyngeal samples